The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

Contrary to the long-held theory of vessel normalization, TKIs in Renal Cell Carcinoma (RCC) work by ablating blood vessels. This induces massive hypoxia, which surprisingly correlates with a better initial therapeutic response, mirroring clinical observations of necrosis in responding tumors.

Combination therapies in RCC are not immunologically equivalent. IO-IO (e.g., Ipi/Nivo) primarily promotes a CD8 T-cell response, associated with durable cures. In contrast, IO-TKI combinations stimulate B-cell and T-follicular helper cell responses, representing a fundamentally different mechanism of action within the tumor microenvironment.

Previous adjuvant trials in kidney cancer using more toxic VEGF-TKIs largely failed. Belzutifan's success suggests that in the adjuvant setting, a drug's tolerability and the ability for patients to maintain dose intensity are more critical for efficacy than raw potency in advanced disease. TKIs were often too toxic for patients to endure for a full year.

Patients progressing on first-generation KRAS G12C inhibitors may still respond to subsequent KRAS-targeted agents. Newer drugs with different binding mechanisms or greater potency are showing response rates over 40% in this post-progression setting, offering a potential new line of therapy.

While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.

Unlike other cancers, re-treating with immunotherapy after recurrence is considered a viable strategy for dMMR endometrial cancer. Experts theorize that these tumors are constantly evolving and may benefit from a "re-education" of the immune system, challenging the conventional wisdom that progression on a drug class means permanent resistance.

The therapeutic effect of TKI-induced hypoxia is a double-edged sword. While it causes initial tumor necrosis and response, preclinical models suggest this same hypoxic environment can promote Epithelial-to-Mesenchymal Transition (EMT), a process that may lead to increased metastatic potential over the long term.